The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided. Said compounds are 9,10 dihydrophenanthrenes, in particular selected from the group consisting of: (i) Lusianthridin i.e. 7-Methoxy-9,10-dihydrophenanthrene-2,5-diol, (ii) 7-Methoxy-9,10-dihydrophenanthrene-2,3,5-triol, (iii) 9,10-dihydrophenanthrene-2,5-diol, (iv) 9,10-Dihydrophenanthrene-2,4,7-triol (v) 9,10-Dihydro-7-methoxy-3,5-phenanthrenediol, and the activation of AMPK improves the condition, disorder, or disease related to cardiometabolic health, obesity, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, and cancer.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

The invention provides a droplet encapsulate comprising: a drop of a hydrophobic medium; a peripheral layer of non-polymeric amphipathic molecules around the surface of the drop; and an aqueous droplet within the peripheral layer, the aqueous droplet comprising: (a) an aqueous medium and (b) an outer layer of non-polymeric amphipathic molecules around the surface of the aqueous medium. The invention also provides processes for preparing the droplet encapsulates. Various uses of the droplet encapsulates are also described, including their use as drug delivery vehicles, in synthetic biology, and in the study of membrane proteins.

The invention provides a droplet encapsulate comprising: a drop of a hydrophobic medium; a peripheral layer of non-polymeric amphipathic molecules around the surface of the drop; and an aqueous droplet within the peripheral layer, the aqueous droplet comprising: (a) an aqueous medium and (b) an outer layer of non-polymeric amphipathic molecules around the surface of the aqueous medium. The invention also provides processes for preparing the droplet encapsulates. Various uses of the droplet encapsulates are also described, including their use as drug delivery vehicles, in synthetic biology, and in the study of membrane proteins.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of 3,3′-dihydroxy-2′,6′-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof.

Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of 3,3′-dihydroxy-2′,6′-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof.

Methods to prevent ketosis or minimize the effects of ketosis in ruminant animals are provided. This methods include feeding to the animal biotin in combination with a mixture of at least two essential oil compounds selected from the group consisting of thymol, eugenol, meta-cresol, vaniline and guajacol. The methods usefully prevent and/or inhibit ketosis of calving ruminant animals and the subsequent need for veterinary treatment. In a preferred embodiment of a feeding concept for dairy cattle, especially calving dairy cattle, biotin is used in an amount sufficient to provide a daily dosage of 10 mg to 20 mg per head to which it is to be administered. It is at present contemplated that the essential oils are administered in amounts (total dosage ranges of essential oils) of 1 to 1.5 g per head per day.

Methods to prevent ketosis or minimize the effects of ketosis in ruminant animals are provided. This methods include feeding to the animal biotin in combination with a mixture of at least two essential oil compounds selected from the group consisting of thymol, eugenol, meta-cresol, vaniline and guajacol. The methods usefully prevent and/or inhibit ketosis of calving ruminant animals and the subsequent need for veterinary treatment. In a preferred embodiment of a feeding concept for dairy cattle, especially calving dairy cattle, biotin is used in an amount sufficient to provide a daily dosage of 10 mg to 20 mg per head to which it is to be administered. It is at present contemplated that the essential oils are administered in amounts (total dosage ranges of essential oils) of 1 to 1.5 g per head per day.